Search

Search Results

• Refractory chronic lymphocytic leukemia

  Giovanni Martinelli

  2009-06-16

  https://doi.org/10.4081/hmr.v1i7.631

  228

  PDF: 458

• Azacytidine: first therapeutic opportunity for myelodysplastic syndromes

  C Finelli, C Bosi, G Martinelli, M Baccarani

  2009-06-08

  https://doi.org/10.4081/hmr.v2i7.415

  237

  PDF: 340

• Ubiquitin-proteasome system is a sensitive target in Ph+ leukemia

  G Martinelli, D Cilloni, G Rosti, P Piccaluga, M Rondoni, C Bosi, S Paolini, F Pane, M Amabile, G Nadali, B Izzo

  2009-06-03

  https://doi.org/10.4081/hmr.v1i8.289

  222

  PDF: 279

• Pha-739358: a pan-aurora kinase inhibitor

  R Paquette, N Shah, C Sawyers, G Martinelli, J Nicoll, M Chalukya

  2009-06-23

  https://doi.org/10.4081/hmr.v2i5.743

  273

  Untitled: 0

  PDF: 456

• New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib

  G Martinelli, I Iacobucci, D Cilloni, P Giannoulia, S Soverini, PP Piccaluga, C Papayannidis, S Paolini, C Terragna

  2009-06-23

  https://doi.org/10.4081/hmr.v2i5.722

  243

  PDF: 243

• Thyrosin kinase inhibitors: nilotinib

  F Castagnetti, F Palandri, G Gugliotta, A Poerio, M Amabile, S Soverini, G Martinelli, M Baccarani, G Rosti

  2009-06-23

  https://doi.org/10.4081/hmr.v2i5.721

  389

  PDF: 476